# US 2021/0080459 A1 · Assays for determinig the pathogencity of toxoplasma infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0080459 A1
- Document ID: US20210080459A1
- Status: Published application
- Kind: A1
- Application number: 17/019,645
- Filed: 2020-09-14
- Published: 2021-03-18
- Earliest claimed: 2016-04-28
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Jianchun Xiao; Robert H. Yolken; Raphael P. Viscidi
- Web page: https://patentgrep.com/patent/US20210080459A1

## CPC

- G01N 33/56905: {Protozoa}
- C07K 16/20: from protozoa
- C12N 1/105: Protozoal isolates
- C12R 2001/90: Protozoa {; Processes using protozoa}
- G01N 2333/45: Toxoplasma
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present invention describes methods of identifying high-risk populations or individuals who have positive serology for T. gondii. These methods include obtaining a biological sample from a subject; determining the level of T. gondii cyst antigen antibody in the biological sample; and characterizing the biological sample in at least one of three categories.

## Claims

### Claim 1

A method of identifying a high-risk population or an individual who has positive serology for T. gondii comprising the following steps:
a. obtaining a biological sample from a subject; and
b. determining the level of T. gondii cyst antigen antibody in the biological sample.

### Claim 2 (depends on 1)

The method of claim 1 further comprising the steps of characterizing the biological sample in at least one of the three categories: (i) high T. gondii cyst antigen antibody level; (ii) low T. gondii cyst antigen antibody level; or (iii) substantially free T. gondii cyst antigen antibody level.

### Claim 3 (depends on 1)

The method of claim 1 wherein the T. gondii cyst antigen is a MAG1 antigen.

### Claim 4 (depends on 3)

The method of claim 3 wherein MAG1 antigen is selected from the group consisting of MAG1_4, MAG1_5, or a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1 wherein the level of T. gondii cyst antigen antibody is determined using ELISA.

### Claim 6 (depends on 5)

The method of claim 5 wherein the biological sample has a high T. gondii cyst antigen antibody level of greater than 0.5 OD.

### Claim 7 (depends on 5)

The method of claim 5 wherein the biological sample has a low T. gondii cyst antigen antibody level in the range of 0.06 to 0.49 OD.

### Claim 8 (depends on 5)

The method of claim 5 wherein the biological sample has a substantially free T. gondii cyst antigen antibody level in the range of 0 to 0.059 OD.

### Claim 9 (depends on 6)

The method of claim 6 comprising an additional step of monitoring the subjects to avoid disease risk.

### Claim 10 (depends on 9)

The method of claim 9 comprising an additional step of treatment to prevent serious disease.

### Claim 11 (depends on 2)

The method of claim 2 wherein the individual is a pregnant woman.

### Claim 12 (depends on 11)

The method of claim 11 wherein the biological sample is characterized as having (i) high T. gondii cyst antigen antibody level and comprising the further step of informing the pregnant woman of an option of an abortion.

### Claim 13 (depends on 2)

The method of claim 2, wherein the individual is a immunocompetent individual.

### Claim 14 (depends on 13)

The method of claim 13 wherein the biological sample is characterized as having (i) high T. gondii cyst antigen antibody level and comprising the further step of monitoring or treating the immunocompetent patient to avoid the incidence of ocular toxoplasmosis or mental disorder.

### Claim 15 (depends on 2)

The method of claim 2 wherein the biological sample is characterized as having (i) high T. gondii cyst antigen antibody level and comprising the further step of monitoring or treating the high risk population to avoid the incidence of ocular toxoplasmosis or mental disorder.

### Claim 16 (depends on 2)

The method of claim 2, wherein the individual is a child.

### Claim 17 (depends on 16)

The method of claim 16, wherein the biological sample is characterized as having (i) high T. gondii cyst antigen antibody level and comprising the further step of treating the child to reduce an incidence of sequelae.

### Claim 18

A kit comprising a T. gondii cyst antigen antibody.

### Claim 19 (depends on 18)

The kit of claim 18, further comprising a T. gondii organism antibody.
